20,000,000

20,000,000

Status: New Submission



For the month ended:

Balance at close of preceding month

Increase / decrease (-)

Balance at close of the month

31 July 2022

# Monthly Return for Equity Issuer and Hong Kong Depositary Receipts listed under Chapter 19B of the Exchange Listing Rules on Movements in Securities

To: Hong Kong Exchanges a	and Clearing Limited								
Name of Issuer:	Fusen Pharmaceutical Company Limited								
Date Submitted:	05 August 2022								
I. Movements in Authoris	sed / Registered Share	e Capital							
1. Type of shares	Ordinary shares		Class of shares	Not appli	cable	Listed on SEHK (Note 1)		Yes	
Stock code	01652	Description	Ordinary	Shares					
		f authorised/registered	d shares	Par val	Par value		Authorised/registered share capital		

2,000,000,000 HKD

2,000,000,000 HKD

Total authorised/registered share capital at the end of the month: HKD 20,000,000

Page 1 of 7 v 1.0.1

0.01 HKD

0.01 HKD

HKD

#### **II. Movements in Issued Shares**

1. Type of shares	Ordinary share:	Class of shares		Not applicable	Listed on SEHK (Note 1)	Yes	
Stock code	01652		Description	Ordinary Shares			
Balance at close of preceding	month		753,439,000				
Increase / decrease (-)			5,000,000				
Balance at close of the month	1	758,439,000					

#### Remarks:

As at 31 July 2022, a total number of 5,000,000 new shares was issued and alloted under RSU Scheme by Fusen Pharmaceutical Company Limited on 29 July 2022

Page 2 of 7 v 1.0.1

#### III. Details of Movements in Issued Shares

## (A). Share Options (under Share Option Schemes of the Issuer)

1. Type of shares issuable	e Ordinary shares		Class of shares Not applica		able Sha		nares issuable to be listed on SEHK (Note 1)			
Stock code of shares issuable (if listed on SEHK) (Note 1)		e 1) 016	552							
Particulars of share option scheme	Number of share options outstanding at close of preceding month	Move	ement during the	month	Number of share opt outstanding at close the month		No. of new shares of issuer issued during the month pursuant thereto (A)	No. of new shares of issuer which may be issued pursuant there as at close of the more	securii issued all sh	total number of ties which may be I upon exercise of are options to be nted under the ne at close of the month
1). Share Option Scheme adopted on 14 June 2018 and granted on 19 July 2019  Exercise period: from 19 October 2019 to 13 Jun 2028  Exercise price: HK \$3.098 per share	9	Others		0	16,00	0,000	0	16,000,	000	80,000,000
General Meeting approval date (if applicable)	14 June 2018								•	

Total A (Ordinary share	es): (
Total funds raised during the month from exercise of options: HKD	(

(B). Warrants to Issue Shares of the Issuer which are to be Listed Not applicable

(C). Convertibles (i.e. Convertible into Issue Shares of the Issuer which are to be Listed) Not applicable

Page 3 of 7 v 1.0.1

## (D). Any other Agreements or Arrangements to Issue Shares of the Issuer which are to be listed, including Options (other than Share Options Schemes)

d on SEHK) (Note 1)  Description  he 2021 RSU Scheme  5,000,000 new shares		-	Total D	General Meeting approval date (if applicable) 31 May 2022 D (Ordinary shares):	the mo	nth purs	f issuer issued during tuant thereto (D) 5,000,000 5,000,000 Company Limited on	issued pur	v shares of is rsuant thereto mont	o as at clos	
he 2021 RSU Scheme		-	Total D	approval date (if applicable) 31 May 2022 D (Ordinary shares):	the mo	nth purs	5,000,000 5,000,000	issued pur	rsuant therete mont	o as at clos	
5,000,000 new shares		-	Total D	O (Ordinary shares):	ısen Pharma	ceutical	5,000,000	  -	22		(
	s was issue				ısen Pharma	ceutical		_	22		
	s was issue				usen Pharma	ceutical		_	22		
	s was issue	ed and allote	d unde	er RSU Scheme by Fu	usen Pharma	ceutical	Company Limited on	29 July 202	22		
	1		Not a	pplicable	Shares	issuable	e to be listed on SEH	K (Note 1, 5	and 6) Yes		
				Issue and allotment date (Note 5 and 6)	approval	date	issued during the	month	which may b	be issued p	ursuan
Currency Amou		mount		adio (rioto o dina o)	(if applicable)		pursuant there	to (E)	month		
.). Repurchase of shares					31 May 2022			0		-7	229,000
229,000 shares was r	epurchase	d by Fusen F	Pharma		,	ŕ	2, but not yet cancelle	0 ed.			
d	Currency 229,000 shares was re	d on SEHK) (Note 1, 5 and 6)  At price (if application of the content of the cont	At price (if applicable)  Currency Amount  229,000 shares was repurchased by Fusen F	At price (if applicable)  Currency Amount  229,000 shares was repurchased by Fusen Pharm.	At price (if applicable)  Currency Amount  State (Note 1, 5 and 6)  Currency Amount  Total E  229,000 shares was repurchased by Fusen Pharmaceutical Company Li	At price (if applicable)  Currency  Amount  Separate Mapproval (if application approval)  Currency  Amount  Total E (Ordinary state)  229,000 shares was repurchased by Fusen Pharmaceutical Company Limited on 2 June 2 Ju	At price (if applicable)  Currency  Amount    Ssue and allotment date (Note 5 and 6)   General Meeting approval date (if applicable)   31 May 2022    Total E (Ordinary shares):	At price (if applicable)  At price (if applicable)  Currency  Amount  See and allotment date (Note 5 and 6)  Total E (Ordinary shares):  229,000 shares was repurchased by Fusen Pharmaceutical Company Limited on 2 June 2022, but not yet cancelled.	At price (if applicable)  At price (if applicable)  At price (if applicable)  Issue and allotment date (Note 5 and 6)  Currency  Amount  Total E (Ordinary shares):  229,000 shares was repurchased by Fusen Pharmaceutical Company Limited on 2 June 2022, but not yet cancelled.	At price (if applicable)    At price (if applicable)   Issue and allotment date (Note 5 and 6)   Issue and allotme	At price (if applicable)  At price (if applicable)  Currency  Amount  Sue and allotment date (Note 5 and 6)  Issue and allotment date (Note 5 and 6)  Issue and allotment date (Note 5 and 6)  Total E (Ordinary shares):  Total E (Ordinary shares):  0  No. of new shares of issuer issued during the month pursuant thereto (E)  Total E (Ordinary shares):  0  229,000 shares was repurchased by Fusen Pharmaceutical Company Limited on 2 June 2022, but not yet cancelled.

Page 4 of 7 v 1.0.1

IV. Information about Hong Kong Depositary Receipt (HDR) Not applicable

Page 5 of 7 v 1.0.1

#### V. Confirmations

We hereby confirm to the best knowledge, information and belief that, in relation to each of the securities issued by the issuer during the month as set out in Part III and IV which has not been previously disclosed in a return published under Main Board Rule 13.25A / GEM Rule 17.27A, it has been duly authorised by the board of directors of the listed issuer and, insofar as applicable:

(Note 2)

- (i) all money due to the listed issuer in respect of the issue of securities has been received by it;
- (ii) all pre-conditions for listing imposed by the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited under "Qualifications of listing" have been fulfilled;
- (iii) all (if any) conditions contained in the formal letter granting listing of and permission to deal in the securities have been fulfilled;
- (iv) all the securities of each class are in all respects identical (Note 3);
- (v) all documents required by the Companies (Winding Up and Miscellaneous Provisions) Ordinance to be filed with the Registrar of Companies have been duly filed and that compliance has been made with other legal requirements;
- (vi) all the definitive documents of title have been delivered/are ready to be delivered/are being prepared and will be delivered in accordance with the terms of issue;
- (vii) completion has taken place of the purchase by the issuer of all property shown in the listing document to have been purchased or agreed to be purchased by it and the purchase consideration for all such property has been duly satisfied; and
- (viii) the trust deed/deed poll relating to the debenture, loan stock, notes or bonds has been completed and executed, and particulars thereof, if so required by law, have been filed with the Registrar of Companies.

Submitted by:	Wong Tik Man

Title: Company Secretary

(Director, Secretary or other Duly Authorised Officer)

#### Notes

- 1. SEHK refers to Stock Exchange of Hong Kong.
- 2. Items (i) to (viii) are suggested forms of confirmation which may be amended to meet individual cases. Where the issuer has already made the relevant confirmations in a return published under Main Board Rule 13.25A / GEM Rule 17.27A in relation to the securities issued, no further confirmation is required to be made in this return.

Page 6 of 7 v 1.0.1

- 3. "Identical" means in this context:
  - . the securities are of the same nominal value with the same amount called up or paid up;
  - they are entitled to dividend/interest at the same rate and for the same period, so that at the next ensuing distribution, the dividend/interest payable per unit will amount to exactly the same sum (gross and net); and
  - . they carry the same rights as to unrestricted transfer, attendance and voting at meetings and rank pari passu in all other respects.
- 4. If there is insufficient space, please submit additional document.
- 5. In the context of repurchase of shares:
  - . "shares issuable to be listed on SEHK" should be construed as "shares repurchased listed on SEHK"; and
  - . "stock code of shares issuable (if listed on SEHK)" should be construed as "stock code of shares repurchased (if listed on SEHK)"; and
  - . "type of shares issuable" should be construed as "type of shares repurchased"; and
  - . "issue and allotment date" should be construed as "cancellation date"
- 6. In the context of redemption of shares:
  - . "shares issuable to be listed on SEHK" should be construed as "shares redeemed listed on SEHK"; and
  - . "stock code of shares issuable (if listed on SEHK)" should be construed as "stock code of shares redeemed (if listed on SEHK)"; and
  - . "type of shares issuable" should be construed as "type of shares redeemed"; and
  - . "issue and allotment date" should be construed as "redemption date"

Page 7 of 7 v 1.0.1